The present study aimed to determine the long-term prognostic validity of the CHA 2 DS 2 -VASc score in patients with acute myocardial infarction (AMI). In addition, we formulated a novel scoring system, the CHA 2 DS 2 -VASc-CF (which includes cigarette smoking and a family history of coronary artery disease as risk factors). This study included 4373 consecutive patients with AMI who presented to the emergency department of our hospital and underwent cardiac catheterization procedures between December 2009 and September 2016. Among these patients, 1427 were diagnosed with ST elevation myocardial infarction (STEMI) and 2946 were diagnosed with non-STEMI. The study included 4373 patients. The study population was divided into 2 groups according to the occurrence of cardiovascular death during the follow-up period. Multivariate logistic regression analysis showed that the CHA 2 DS 2 -VASc-CF score, CHA 2 DS 2 -VASc score, major adverse cardiac events, current cigarette smoking, older age, hypertension, and family history of coronary artery disease were significantly higher, and that the left ventricular ejection fraction and glomerular filtration rate were significantly lower in the cardiovascular death (þ) group. Using a cutoff score of >3 for the CHA 2 DS 2 -VASc-CF score, long-term cardiovascular death was predicted with a sensitivity of 78.4% and specificity of 76.4%. The CHA 2 DS 2 -VASc-CF score is suitable for use in all patients with AMI, regardless of the type of treatment, presence of atrial fibrillation, and type of AMI. This risk score, which is easy to calculate, provides important prognostic data. In the future, we think that interventional cardiologists will be able to use this novel scoring system to identify patients with a high risk of long-term cardiovascular death.
Introduction
As the incidence of acute myocardial infarction (AMI) increased and the acute coronary events survival rate improved, the riskstratification system used for long-term post-AMI prognosis increased in importance. All patients with AMI should undergo early and late risk stratification. Early risk stratification in patients with non-ST elevation myocardial infarction (NSTEMI) provides a guide to the in-hospital treatment decision-making process, especially early invasive treatment, whereas late risk stratification aids long-term patient management and the prediction of prognosis. 1 Patients with ST elevation myocardial infarction (STEMI) should undergo early and late risk stratification as well, but early reperfusion is the first-line choice of treatment, even in cases with low risk at initial evaluation. Late risk stratification in patients with STEMI should be used to identify patients with increased risk of cardiovascular mortality. 2 Early and late risk stratification in patients with AMI is intended to identify high-risk patients, as such patients benefit most from aggressive treatment. There are various risk prediction models for patients with NSTEMI and STEMI. The Thrombolysis in Myocardial Infarction (TIMI) risk score and Global Registry of Acute Coronary Events (Grace) Risk score are the most commonly used risk prediction scores. [3] [4] [5] The CHA 2 DS 2 -VASc score is a simple scoring system used to predict thromboembolic risk in patients with atrial fibrillation and considers such risk factors for cardiovascular mortality as heart failure and age. The long-term validity of the CHADS 2 scorethe predecessor of the CHA 2 DS 2 -VASc score-as a prognostic marker in patients with AMI, independent of atrial fibrillation, has been reported. 6 Recent studies have shown that the CHA 2 DS 2 -VASc score can be considered a prognostic marker of in-hospital and long-term mortality in patients with STEMI. 7, 8 The present retrospective cohort study aimed to determine the long-term prognostic validity of the CHA 2 DS 2 -VASc score in patients with AMI. In addition, we formulated a novel scoring system, the CHA 2 DS 2-VASc-CF (which includes cigarette smoking and a family history of coronary artery disease [CAD] as risk factors) and compared the risk prediction of this novel risk score with that of the CHA 2 DS 2 -VASc score.
Materials and Methods
This single-center study included 4373 consecutive patients with AMI who presented to the emergency department of our hospital and underwent cardiac catheterization procedures between December 2009 and September 2016. Follow-up data were obtained from digital records, patient files, or by telephone interview with patients, family members, or primary care physicians. Among these patients, 1427 were diagnosed as STEMI and 2946 were diagnosed as NSTEMI. ST elevation myocardial infarction was defined as ischemic symptoms for !10 minutes at rest within 72 hours of presentation and electrocardiographic changes associated with STEMI (new left bundle-branch block or persistent ST segment elevation >1 mm in !2 contiguous electrocardiographic leads). Non-ST elevation myocardial infarction was defined as ischemic symptoms for !10 minutes at rest that occurred within 24 hours of presentation and elevated cardiac markers of necrosis (troponin I). 9 Patients with a history of or newly diagnosed atrial fibrillation, those with unstable angina pectoris, and those in which an intracoronary lesion was not observed via angiography were excluded.
The study population was divided into 2 groups according to the occurrence of cardiovascular death during the follow-up period. The CHA 2 DS 2 -VASc score and CHA 2 DS 2-VASc-CF score were calculated separately on the patients' index events. Next, the patients were divided into 4 groups according to their CHA 2 DS 2-VASc-CF score. All the parameters included in these scores were obtained from the hospital database. In addition, demographic, clinical, laboratory, and echocardiographic data were collected from the patients' electronic medical records, via telephone contact (with either the general practitioner or the patient), and via coupling of municipal mortality records or information system. The components of CHA 2 DS 2 -VASc score and CHA 2 DS 2--VASc-CF score include congestive heart failure (1 point), hypertension (1 point), age (>75 years [2 points]), diabetes mellitus (1 point), history of stroke or transient ischemic attack (2 points), history of vascular disease (1 point), age (>65 years [1 point]), female gender (1 point), cigarette smoking (1 point), and family history of premature CAD (1 point). 10 Hypertension was defined as a history of antihypertensive medication use, systolic blood pressure !140 mm Hg, or diastolic blood pressure !90 mm Hg. Diabetes mellitus was defined as a history of use of insulin or antidiabetic agents, or a fasting glucose level !126 mgdL -1 . Chronic heart failure was defined as a <40% decrease in the left ventricular ejection fraction or congestive heart failure. Vascular disease was defined as a history of MI, peripheral arterial disease, or complex aortic plaques. A family history of CAD was defined as !1 first-degree relatives with premature CAD (in men before the age of 55 years and in women before the age of 65 years). Mortality due to AMI, sudden cardiac death or arrhythmia, heart failure, and stroke were considered cardiovascular death. Major adverse cardiac events (MACEs) were defined as cardiovascular death, reinfarction, and repeat target vessel revascularization. The study protocol was approved by the Ankara Numune Education and Research Hospital Ethics Committee. Univariate logistic regression analysis was used to calculate the effects of multiple variables on cardiovascular death. Variables with an unadjusted P value <.05 based on logistic regression analysis were considered potential risk markers and were included in the multivariate logistic regression analysis model. Potential risk markers were eliminated using forward stepwise multivariate logistic regression analysis. P values <.05 were considered statistically significant at the 95% confidence interval (CI). The receiver-operating characteristics (ROC) curve was used to show the sensitivity and specificity of CHA 2 DS 2--VASc and CHA 2 DS 2-VASc-CF scores and the optimal cutoff value of each for predicting long-term cardiovascular death.
Statistical Analysis
Finally, the study population was divided into quartiles for descriptive purposes according to the CHA 2 DS 2-VASc-CF score. We used Cox regression modeling to examine the association between CHA 2 DS 2-VASc-CF score quartiles and cardiovascular death. Kaplan-Meier estimate curves were used to determine the correlations between CHA 2 DS 2-VASc-CF score quartiles, MACEs, and cardiovascular death.
Results
The study included 4373 patients. Baseline demographic and clinical data according to the occurrence of cardiovascular death are shown in Table 1 . The follow-up period and body mass index did not differ significantly between the patients with and without cardiovascular death. Mean age of patients in the cardiovascular death (À) group was significantly higher than in the cardiovascular death (þ) group. The prevalence of diabetes mellitus, hypertension, hyperlipidemia, a family history of CAD, the number of female patients, and current cigarette smoking, and type of MI, hemoglobin A 1 C level, MACEs, and CHA 2 DS 2 -VASc and CHA 2 DS 2 -VASc-CF scores were higher in the cardiovascular death (þ) group. On the other hand, the left ventricular ejection fraction and the glomerular filtration rate were lower in the cardiovascular death (þ) group.
The parameters with P values <.05 based on univariate logistic regression analysis were used for multivariate logistic regression analysis (age, female gender, diabetes mellitus, hypertension, current cigarette smoking, hyperlipidemia, family history of CAD, type of MI, hemoglobin A 1 C, left ventricular ejection fraction, glomerular filtration rate, MACEs, CHA 2 DS 2 -VASc score, and CHA 2 DS 2 -VASc-CF score). This multivariate logistic regression analysis showed that the CHA 2 DS 2 -VASc-CF score, CHA 2 DS 2 -VASc score, MACEs, current cigarette smoking, older age, hypertension, and family history of CAD were significantly higher and that the left ventricular ejection fraction and glomerular filtration rate were significantly lower in the cardiovascular death (þ) group (Table 2 ). The ROC curve was used to analyze the discriminatory capability of the CHA 2 DS 2 -VASc score and CHA 2 DS 2 -VASc-CF score to predict long-term cardiovascular death; the area under the curve was 0.739 (95% CI: 0.715-0.763; P < .001) and 0.840 (95% CI: 0.815-0.862; P< .001), respectively. Using a cutoff score of >2 for the CHA 2 DS 2 -VASc score and >3 for the CHA 2 DS 2 -VASc-CF score, long-term cardiovascular death was predicted with a sensitivity of 61.5% and specificity of 74.2%, and a sensitivity of 78.4% and specificity of 76.4%, respectively (Figure 1 ). Descriptive and the results of Cox regression analysis for predicting long-term cardiovascular death according to CHA 2 DS 2 -VASc-CF score are shown in Table 3 . For descriptive purposes, the patients were divided into 4 groups according to their CHA 2 DS 2 -VASc-CF score (Table 3) as follows: group 1: 1; group 2: 2-3; group 3:4-5; and group 4: !6). Long-term cardiovascular mortality was found to be significantly different among the CHA 2 DS 2 -VASc-CF score groups. As shown in Table 3 , group 4 has the highest percentage of long-term cardiovascular mortality (P < .001).
The Kaplan-Meier MACEs and survival estimate curves for each of the CHA 2 DS 2 -VASc-CF score groups are shown in Figures 2 and 3 , respectively. As shown in these figures, the occurrence of both MACEs (Figure 2 ) and long-term cardiovascular mortality (Figure 3 ) significantly increased in higher CHA 2 DS 2 -VASc-CF groups.
Discussion
The present study's most important finding is that the CHA 2 DS 2 -VASc-CF score at presentation can predict longterm cardiovascular death better than the CHA 2 DS 2 -VASc score. A CHA 2 DS 2 -VASc-CF score >3 can predict long-term cardiovascular death, with a sensitivity of 78.4% and specificity of 76.4%. In addition, long-term MACEs can also be predicted using this novel score. Furthermore, the CHA 2 DS 2 -VASc-CF score can be used as a risk-stratification system in patients with AMI, irrespective of the type of MI, presence of atrial fibrillation, and type of treatment.
Most patients with CAD have at least 1 coronary risk factor; the presence of more than one of these risk factors increases the risk of CAD. 11, 12 It is of great importance to assess the risk of CAD to provide appropriate medical treatment and account for morbidity and mortality. Therefore, several risk prediction algorithms, including major CAD risk factors, have been developed. Clinicians need simple, reliable, reproducible, and quantitative tools to identify patients' risks and recommend prevention strategies. Although the GRACE and TIMI risk scores are well-known for risk stratification in patients with AMI and are recommended by multiple organizations, these risk scores require a computerized system. [3] [4] [5] In contrast to the complexity of the GRACE and TIMI risk scores, the CHADS 2 score is a fast, wide-ranging, and practical for risk stratification. 13 As the predictive power of the CHA 2 DS 2 -VASc score is greater than that of the CHADS 2 score, it is reasonable to use CHA 2 DS 2 -VASc score to easily and accurately predict long-term cardiovascular death in patients with AMI. Likewise, Bozbay et al 7 and Kim et al 8 reported that the CHA 2 DS 2 -VASc score is a powerful predictor of cardiovascular death in patients with AMI, 7, 8, 14 and Cetin et al 15 suggested that the CHA 2 DS 2 -VASc score is independently correlated with the severity of CAD. In another study, Kurtul et al demonstrated that CHA 2 DS 2 -VASc score can predict contrastinduced nephropathy after percutenous coronary intervention for acute coronary syndrome. 16 The CHA 2 DS 2 -VASc score was developed to improve risk stratification in patients with atrial fibrillation patients and a low CHADS 2 score (0-1); patient aged 65 to 74 years, female gender, and vascular disease are additional components of the CHADS 2 score. All the components of the CHA 2 DS 2 -VASc score are important risk and prognostic factors for cardiovascular disease. It was reported that in-hospital mortality significantly and independently increases as patient age increases. 17 Gustafsson et al 18 observed that hypertension, diabetes mellitus, and a low left ventricular ejection fraction are long-term prognostic predictors following AMI. Malmberg et al 19 also reported that diabetes mellitus was an independent predictor of all-cause mortality and cardiovascular death in patients with unstable angina or NSTEMI. Reynolds et al 20 reported that according to multivariate analysis, women have a higher (not significantly) risk of cardiovascular death post-AMI than men. Additionally, Ducrocq et al 21 noted that a history of stroke is associated with an independent increase in the risk of AMI and death. A large-scale, long-term follow-up study reported that a history of peripheral arterial disease is a critical evidence of more widespread atherothrombotic disease and a substantial risk of subsequent cardiovascular events and death 22 ; therefore, all components of the CHA 2 DS 2 -VASc score are closely associated with clinical outcome in patients with AMI. Cigarette smoking and a family history of CAD are also well-known independent risk factors for cardiovascular events. 23 In the present study, not surprisingly, these 2 risk factors were also observed to be independent and significant predictors of longterm cardiovascular death; however, these well-known risk factors had not been used together with the CHA 2 DS 2 -VASc.
As such, in the present study, these 2 risk factors were added to the CHA 2 DS 2 -VASc score model (CHA 2 DS 2 -VASc-CF), and this novel scoring model was better at predicting longterm cardiovascular death than the standard CHA 2 DS 2 -VASc score. In addition, this novel risk scoring model also predicted the occurrence of MACEs. Using a cutoff score >3, this novel scoring system predicted long-term cardiovascular death with a sensitivity of 78.4% and specificity of 76.4%. The outcomes of high-risk patients can be predicted using this scoring system, without the need for information regarding vital signs at admission, which is convenient for the rapid screening of high-risk patients in clinics. The CHA 2 DS 2 -VASc-CF risk score, which is easy to calculate and does not require any software to calculate the total risk assessment, provides important prognostic data. The present findings show that the CHA 2 DS 2 -VASc-CF score is an independent and powerful predictor of long-term cardiovascular death and MACEs in patients with AMI, and that it can be used for risk stratification. In the future, we believe that interventional cardiologists will be able to use this novel scoring system to identify patients with a high risk of long-term cardiovascular death and MACEs because the CHA 2 DS 2 -VASc-CF score is suitable for use in all patients with AMI, regardless of the type of treatment, presence of atrial fibrillation, and type of AMI.
Limitations
The present study has some limitations, including its nonrandomized single-center design and lack of calculation of other clinical and angiographic risk scores, such as TIMI, GRACE, and Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX). Finally, despite including a large patient cohort, they were retrospectively analyzed. We think additional prospective studies are needed to evaluate the prognostic role of the CHA 2 DS 2 -VASc-CF score with greater accuracy. 
